Sesame, a healthcare marketplace, has launched a new clinical weight loss program offering compounded versions of the obesity drug Wegovy for $249 per month. The program aims to provide an affordable alternative amid a shortage of brand-name GLP-1 drugs like Wegovy and Ozempic, which typically cost $1,000 per month. Sesame's initiative includes consultations, lab work, and a content library for ongoing support. The program partners with a 503B compounding pharmacy to ensure safety and quality, addressing concerns about the purity of compounded medications.